Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

American Journal of Transplantation

Volumn 5, Issue 10, 2005, Pages 2521-2530

  Vítko, Štefan ^a   Margreiter, Raimund ^b   Weimar, Willem ^c   Dantal, Jacques ^d   Kuypers, Dirk ^e   Winkler, Michael ^f   Øyen, Ole ^g   Viljoen, Hendrik G ^h   Filiptsev, Pavel ⁱ   Sadek, Sami ^j   Li, Yulan ^k   Cretin, Nathalie ^k   Budde, Klemens ^l  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b Universitatsklinik fur Chirurgie Innsbruck   (Austria)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d HÔTEL DIEU   (France)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h Garden City Hospital   (South Africa)

ⁱ City Hospital No 36   (Russian Federation)

^j QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^k NOVARTIS PHARMA AG   (Switzerland)

^l CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

Cytomegalovirus; Everolimus; Kidney transplant; Mycophenolate mofetil; Rejection

Indexed keywords

ANTILIPEMIC AGENT; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; CYCLOSPORIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN;

ACUTE GRAFT REJECTION; ANEMIA; ARTICLE; BACTERIAL INFECTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LYMPHOCELE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MICROEMULSION; MORTALITY; MULTICENTER STUDY; MYCOSIS; PATIENT MONITORING; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; RENAL GRAFT DYSFUNCTION; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VIRUS INFECTION; ADOLESCENT; ADULT; AGED; BIOPSY; BLOOD; COHORT ANALYSIS; EMULSION; FEMALE; GRAFT REJECTION; KIDNEY; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; BIOPSY; COHORT STUDIES; CREATININE; CYCLOSPORINE; DOUBLE-BLIND METHOD; EMULSIONS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33644696712     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.01063.x     Document Type: Article

References (31)

1. Olyaei AJ de Mattos AM Bennett WM. Nephrotoxicity of immunosuppressive drugs: New insight and preventive strategies. Curr Opin Crit Care 2001 7 : 384 389.
2. Sehgal S. Rapamune (Sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit 1995 17 : 660 665.
3. Schuler W Sedrani R Cottens S et al. SDZ RAD, a new rapamycin derivative. Pharmacologic properties in vitro and in vivo. Transplantation 1997 64 : 36 42.
4. Schuurman HJ Cotton S Fuchs S et al. SDZ RAD, a new rapamycin derivative: Synergism with cyclosporine. Transplant 1997 64 : 32 35.
5. Eisen HJ Tuzcu EM Dorent R et al. for the RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003 349 : 847 858.
6. Nankivell BJ Borrows RJ Fung CL O'Connell PJ Allen RD Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003 349 : 2326 2333.
7. Gourishankar S Halloran PF. Call for revolution: A new approach to describing allograft deterioration. Am J Transplant 2002 Mar 2 : 195 200.
8. Nashan B. The role of Certican™ (everolimus, RAD) in the many pathways of chronic rejection. Transplant Proc 2001 33 : 3215 3220.
9. Srinivas TR Kaplan B Meier-Kriesche HU. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 2003 4 : 2325 2345.
10. Halloran P Mathew T Tomlanovich S Groth C Hooftman L Barker C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997 63 : 39 47.
11. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999 68 : 391 396.
12. Ojo AO Meier-Kriesche HU Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000 69 : 2405 9.
13. Kaufman DB Shapiro R Lucey MR Cherikh WS Bustami RT Dyke DB. Immunosuppression: Practice and trends. Am J Transplant 2004 4 ( Suppl 9 38 53.
14. Vítko S Margreiter R Weimar W et al. Everolimus (Certican™) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004 78 : 1532 1540.
15. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004 351 : 2715 2729.
16. Mathew TH, for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation. Transplantation 1998 65 : 1450 1454.
17. Kreis H Oberbauer R Campistol JM et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004 15 : 809 817.
18. Lorber MI Mulgaonkar S Butt KMH et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study. Transplantation 2005 80 : 244 252.
19. Nashan B Curtis J Ponticelli C Mourad G Jaffe J Haas T, for the 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multicenter, open-label study. Transplantation 2004 78 : 1332 1340.
20. Kovarik JM Kahan BD Kaplan B Lorber M Winkler M Rouilly M. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther 2001 69 : 48 56.
21. Kovarik JM Kaplan B Silva HT et al. Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range. Transplantation 2002 73 : 920 925.
22. Kovarik JM Kaplan B Silva HT et al. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am J Transplant 2003 3 : 606 613
23. Costa RA Lansky AJ Mintz GS et al. Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial). Am J Cardiol 2005 95 : 113 116.
24. Vitko S Tedesco H Eris J. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004 4 : 625 635.
25. Kovarik J. Everolimus: A proliferation signal inhibitor targeting primary causes of allograft dysfunction. Drugs Today 2004 40 : 101 109.
26. Humar A Gillingham KJ Payne WD et al. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999 68 : 1879 1883.
27. Schnitzler MA. Costs and consequences of cytomegalovirus disease. Am J Health Syst Pharm 2003 60 ( Suppl 8 S5 S8.
28. Kaplan B Srinivas TR Meier-Kriesche HU. Factors associated with long-term renal allograft survival. Ther Drug Monit 2002 24 : 36 39.
29. Meier-Kriesche HU Steffen BJ Chu AH et al. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival. Am J Transplant 2004 4 : 2058 2066.
30. Kuypers DR. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf 2005 28 : 153 181.
31. Mota A. Sirolimus: A new option in transplantation. Expert Opin Pharmacother 2005 6 : 479 487.